Non-Hodgkin Lymphoma
Conference Coverage
Timing Is Everything: CAR T for Follicular Lymphoma
Experts debated about whether and when patients with relapsed/refractory follicular lymphoma should receive CAR T-cell therapy.
From the Journals
Most Targeted Cancer Drugs Lack Substantial Clinical Benefit
Researchers assess validity of the molecular targets and clinical benefits of genome-targeted cancer drugs approved in the United States from 2015...
Conference Coverage
No Routine Cancer Screening Option? New MCED Tests May Help
CanScan, MERCURY, and OncoSeek can detect a range of cancers and recognize the tissue of origin with high accuracy.
From the Journals
Oncologists Voice Ethical Concerns Over AI in Cancer Care
Researchers ask 204 oncologists from 37 states for their views on the ethical implications of using AI for cancer care.
From the Journals
Less Than 50% of Accelerated Approvals Show Clinical Benefit
Researchers review 46 cancer drugs granted accelerated approvals between 2013 and 2017.
From the Journals
Virtual Reality Brings Relief to Hospitalized Patients With Cancer
Patients were randomized to receive either 10 minutes of immersive VR distraction therapy or 10 minutes of two-dimensional guided imagery...
Feature
Should Opioids Be Used for Chronic Cancer Pain?
Prescribing strategies are partly driven by peer pressure, new research suggests.
Feature
Blood Cancer Emergencies: Hematologists’ Late-Night Calls
Blood cancer conditions such as leukocytosis, tumor lysis syndrome, and differentiation syndrome can require urgent treatment.
From the Journals
Active Surveillance for Cancer Doesn’t Increase Malpractice Risk
Researchers identify malpractice trends involving active surveillance related to thyroid, prostate, kidney, and...
News
FDA’s Cancer-Drug Rebuff Hints at Stricter Stance
Does the FDA’s refusal to grant accelerated approval for odronextamab mean US regulators are taking a stricter stance on confirmatory trials?
From the Journals
Few Childhood Cancer Survivors Get Recommended Screenings
‘As many as four out of five of these survivors will develop a serious or life-threatening late effect of their cancer therapy by age 45,’ the...